News Medical

Test document

This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...
ascopubs.org

A randomized open-label study of darbepoetin alfa administered every 3 weeks with or without parenteral iron in anemic subjects with nonmyeloid malignancies receiving chemotherapy

Does one person provide it all? Defining the social support of women with cancer Pts with adverse events - n (%) 46 (79) 49 (88) 95 (83) Pts with serious adverse events - n (%) 18 (31) 21 (38) 39 (34) ...
Nature

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

Patients with low or intermediate-1 (int-1) International Prognostic Scoring System (IPSS) risk myelodysplastic syndromes (MDS) have a median survival of 5.7 and 3.5 years, respectively, when treated ...